Filing summary
Entity and period: The supplied filing is OncoGenex Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 26, 2015. This does not match the request metadata naming Achieve Life Sciences, Inc. or “2014 Q4.” The company was a clinical-stage cancer therapeutics developer with no approved products or product-sales revenue.
Financial performance and condition
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Collaboration revenue | $27.1 million | $29.9 million |
| Research and development expense | $46.2 million | $55.3 million |
| General and administrative expense | $10.6 million | $9.9 million |
| Net loss | $26.2 million | $31.8 million |
| Loss per share, basic and diluted | $1.45 | $2.17 |
| Cash, cash equivalents and short-term investments at year-end | $47.1 million | $39.2 million |
| Total assets / total liabilities | $56.3 million / $22.2 million | $55.7 million / $18.5 million |
- Revenue came entirely from the Teva collaboration, including reimbursement of development costs; the company reported no product sales. Revenue fell 9% year over year, principally because of lower reimbursable combination-drug purchases for the AFFINITY trial.
- Operating cash use was $17.3 million, down from $35.9 million in 2013. Financing provided $25.2 million, mainly from a July 2014 offering and at-the-market share sales; investing activities provided $5.4 million, primarily reflecting investment maturities and purchases.
- Year-end current assets were $55.8 million and current liabilities $22.2 million. Accumulated deficit was $160.0 million. The balance sheet included $3.0 million of warrant liabilities and approximately $0.25 million of current and long-term obligations; the filing does not identify material conventional borrowing.
- Reported net loss included a $3.7 million noncash gain from revaluing warrants. The warrant valuation depends on estimates and can cause earnings volatility. No product margins were reported; collaboration revenue was below R&D expense.
Material developments and outlook
- Clinical results: The phase 3 SYNERGY trial of custirsen in first-line metastatic castration-resistant prostate cancer failed its primary overall-survival endpoint: median survival was 23.4 months with custirsen plus docetaxel versus 22.2 months with docetaxel alone (HR 0.93; one-sided p=0.207). Exploratory analyses suggested benefit in a poor-prognosis subgroup, but these findings were not the primary result.
- Ongoing trials: AFFINITY, a phase 3 prostate cancer trial, passed an interim futility analysis in January 2015 after enrollment of about 630 patients. ENSPIRIT, a phase 3 non-small-cell lung cancer trial, passed its first interim futility analysis in August 2014. Management planned to modify ENSPIRIT’s design and conduct a more rigorous second futility analysis. Apatorsen’s phase 2 Borealis-1 bladder cancer trial reported exploratory signals, including a lower risk of death at the 600 mg dose; the filing emphasizes that further analyses were pending.
- Teva collaboration: In December 2014, OncoGenex and Teva agreed to negotiate a termination of their collaboration; negotiations remained ongoing at filing. If terminated, the company expected to assume future custirsen development costs and receive no further Teva payments except any termination payment. Management expected approximately $27 million, subject to adjustments, under the contemplated terms; receipt and final terms were not assured.
- Liquidity outlook: Management believed existing resources would fund planned operations into the third quarter of 2016, including specified trial milestones and a modified ENSPIRIT futility analysis. Continuing ENSPIRIT beyond that analysis would require additional capital. The estimate depended on assumptions that could prove wrong, and the company warned it might need funding sooner.
- Other items: A February 2015 agreement terminated the Bothell facility lease effective March 1, 2015, with a $2.0 million fee and a further contingent $1.3 million fee tied to clinical and financing conditions. The company planned to move to smaller office space. The stock price fell sharply during 2014; the filing cites clinical results and financing/dilution risks. Auditors issued unqualified opinions on the financial statements and internal control over financial reporting.
Key facts for investors to verify
- Confirm the issuer and reporting period: the filing is for OncoGenex Pharmaceuticals, Inc., not Achieve Life Sciences, Inc., and covers FY 2014 rather than a standalone Q4 filing.
- Check the final Teva termination agreement, any termination proceeds and the transfer of responsibility for custirsen trials and costs.
- Review AFFINITY and ENSPIRIT trial updates, including futility decisions, design changes, final results and funding needs.
- Assess whether subgroup findings from SYNERGY and Borealis-1 are confirmed in further analyses and adequately supported by trial data.
- Reconcile the cash runway assumptions with actual spending, contingent lease fees and any new financing; consider dilution from outstanding warrants and the at-the-market program.